Abbott's Esprit BTK System Gains the US FDA’s Approval for Chronic Limb-Threatening Ischemia (CLTI) Below-The-Knee (BTK)
Shots:
- The US FDA has approved Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System) intended for chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)
- The approval was based on the LIFE-BTK study that assessed the Esprit BTK System & depicted reduction in disease progression plus improved clinical outcomes vs balloon angioplasty (current SoC). The results were highlighted at 35th TCT Conference in Oct 2023 & published in The New England Journal of Medicine
- The Esprit BTK System is a dissolvable stent that opens the blockage, transfers Everolimus & promotes vessel healing before dissolving. It supports the vessels for ~3yrs. enabling them to stay open independently
Ref: Abbott | Image: Abbott
Related News:- Abbott Reports Trial Results for Esprit BTK in Chronic Limb-Threatening Ischemia (CLTI)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
